Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
IDEXX Laboratories Inc Market Cap
From what 10 stock analysts predict, the share price for IDEXX Laboratories Inc (IDXX) might increase by 11.2% in the next year. This is based on a 12-month average estimation for IDXX. Price targets go from $405.12 to $607. The majority of stock analysts believe IDXX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
IDXX is a stock in Healthcare which has been forecasted to be worth $531.19 as an average. On the higher end, the forecast price is $607 USD by from and on the lower end IDXX is forecasted to be $405.12 by from .
These are the latest 20 analyst ratings of IDXX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Westenberg Piper Sandler | Neutral | $520 | Maintains | Aug 14, 2024 |
| Mark Massaro BTIG | Buy | $580 | Initiates | Jul 25, 2024 |
| Jonathan Block Stifel | Hold | $510 | Maintains | Jun 24, 2024 |
| Erin Wright Morgan Stanley | Overweight | $596 | Maintains | May 14, 2024 |
| Balaji Prasad Barclays | Overweight | $570 | Maintains | May 2, 2024 |
| Chris Schott JP Morgan | Overweight | $630 | Maintains | Feb 6, 2024 |
| Balaji Prasad Barclays | Overweight | $655 | Maintains | Feb 6, 2024 |
| David Westenberg Piper Sandler | Neutral | $525 | Downgrade | Jan 30, 2024 |
| Nathan Rich Goldman Sachs | Buy | $650 | Maintains | Jan 17, 2024 |
| David Westenberg Piper Sandler | Overweight | $525 | Maintains | Nov 6, 2023 |
| Nathan Rich Goldman Sachs | Buy | $500 | Maintains | Nov 3, 2023 |
| Balaji Prasad Barclays | Overweight | $592 | Maintains | Nov 2, 2023 |
| Chris Schott JP Morgan | Overweight | $550 | Maintains | Nov 2, 2023 |
| Jonathan Block Stifel | Hold | $460 | Maintains | Oct 30, 2023 |
| Jonathan Block Stifel | Hold | $500 | Maintains | Sep 15, 2023 |
Morgan Stanley | Overweight | Maintains | Aug 3, 2023 | |
Atlantic Equities | Neutral | Downgrade | Aug 2, 2023 | |
JP Morgan | Overweight | Maintains | Aug 2, 2023 | |
| Steve Chesney Atlantic Equities | Overweight | $600 | Reiterates | Jun 7, 2023 |
| Steve Chesney Atlantic Equities | Overweight | $600 | Reiterates | May 3, 2023 |
When did it IPO
1991
Staff Count
11,000
Country
United States
Sector/Industry
Healthcare/Diagnostics & Research
CEO
Mr. Jonathan J. Mazelsky
Market Cap
$39.65B
In 2023, IDXX generated $3.66B in revenue, which was a increase of 8.72% from the previous year. This can be seen as a signal that IDXX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Sep 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Idexx (IDXX) recently reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for potential stock performance insights.
Why It Matters - Idexx's recent earnings report can indicate its financial health and growth potential, influencing stock performance and investor sentiment in the veterinary diagnostics sector.
Wed, 21 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - IDEXX Laboratories' CEO Jay Mazelsky and CFO Brian McKeon will speak at the Morgan Stanley Global Healthcare Conference on September 4, 2024. A live audio webcast will be available.
Why It Matters - IDEXX's leadership participation in a major healthcare conference signals commitment to transparency and growth, potentially influencing investor confidence and stock performance.
Sun, 11 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - IDEXX's full-year organic revenue growth declined due to fewer U.S. clinical visits. Ongoing staffing challenges and weak consumer sentiment may persist. A new Catalyst platform menu could boost diagnostics.
Why It Matters - IDEXX's lower organic revenue growth signals potential challenges ahead, impacting profitability. Staffing issues and weak consumer sentiment could hinder recovery, while overvaluation raises investment risk.
Tue, 06 Aug 2024
Sentiment - POSITIVE
Source - Benzinga
Summary - Idexx Laboratories reported Q2 adjusted EPS of $3.02, a 15% year-over-year increase, surpassing the consensus estimate of $2.88.
Why It Matters - Idexx's strong EPS growth and beat on consensus indicate robust financial health and operational efficiency, potentially driving investor confidence and stock performance.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - IDEXX Laboratories held its Q2 2024 Earnings Conference Call on August 6, 2024, featuring key executives and analysts from major financial institutions.
Why It Matters - The earnings call provides insights into IDEXX's financial performance and strategic direction, influencing stock valuation and investor sentiment.
Tue, 06 Aug 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - IDEXX Laboratories reported Q2 2024 revenues of $1,004 million, up 6% overall and 7% organically, driven by 6% growth in Companion Animal Group and 9% in Water revenue.
Why It Matters - IDEXX Laboratories' strong revenue growth, especially in the Companion Animal Group and Water segments, signals robust demand and operational health, potentially boosting investor confidence and stock performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
